Nxera Pharma Co., Ltd. 4565

Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has entered into a settlement agreement with OMass Therapeutics Limited (“OMass”) in relation to OMass’ past infringement of patents EP 3 408 286 B1 and GB 2 558 968 B relating to Nxera’s proprietary miniG platform technology. The settlement resolves the patent infringement proceedings brough

Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly and Company (“Lilly”), has achieved a late-stage development milestone associated with its selective orexin receptor 2 (OX2R) agonist portfolio. This milestone triggers a payment of US$8.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone packageNxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd.

Tokyo, Japan and Cambridge, UK, 7 August 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June 2026. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “During the second quarter of FY2026, we continued to make steady progress across the business, building on the momentum achieved in the first quarter. Revenues from PIVLAZ® and QUVIVIQ®

Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026. The webinar is open to all existing and potential i

This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaborationUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales Tokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reache

Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, bi

BERKELEY, Calif., June 09, 2026--AI can predict a protein’s 3D shape and help design molecules that fit it. Tools like OpenFold make drug discovery faster, cheaper, and more precise.

The alcohol use disorder market is set to grow due to unmet clinical needs, limited efficacy of current therapies, and rising demand for better-tolerated treatments. Expanding label indications, new regulatory approvals of therapies such as AD04 (ondansetron) (Adial Pharmaceuticals), Brenipatide (LY3537031) (Eli Lilly and Company), MN-166 (ibudilast) (MediciNova), Sunobinop (V117957) [Imbrium Therapeutics (subsidiary of Purdue Pharma)], Pemvidutide (Altimmune), TMP-301/HTL0014242 (Tempero Bio an

Pratteln, Switzerland, June 2, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that AGAMREE has been granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation by South Korea’s Ministry of Food and Drug Safety (MFDS) for the treatment of Duchenne muscular dystrophy (DMD). These designations recognize the significant unmet medical need among DMD patients in South Korea, where no alternative treatment is currently available. The GIFT designation i

Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need without an established treatment in South Korea.Global Innovative Products on Fast Track (GIFT) designation, a priority review pathway introduced by Korea's Ministry of Food and Drug Safety, may support accelerated regulatory review and faster patient access to innovative therapies in South Korea.Nxera plans to submit a Marketing Authorization Application for vamorolone in S

Tokyo, Japan and Cambridge, UK, 26 May 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference on Wednesday,3rd June at 3:45 p.m. EDT / 4th 4:45 a.m. JST. During the event, Mr. Cargill will present the Company’s strategy, recent progress and expected upcoming milestones to leading global life sciences investors. The live webcast of the ‘Fireside Chat’ wil

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.Builds toward the establishment of

Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has issued proceedings against OMass Therapeutics alleging infringement of its patents EP 3 408 286 B1 and GB 2 558 968 B relating to its proprietary miniG technology. miniG is an integral part of Nxera’s NxWave™ GPCR-focused structure-based drug discovery platform. The proceedings have been commenc

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release AGAMREE® delivers strong growth as global expansion accelerates Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2025. Dario Eklund, CEO of Santhera, said: “Our strong performance in 2025 reflects the continued momentum of AGAM

Discover comprehensive insights into the Singapore data center market with our Excel database. Gain detailed analysis of 45 existing and 6 upcoming data centers across Eastern, Southern, Northern, and Western Singapore. The database covers key metrics including white-floor space, IT load capacity, and colocation pricing. Notable operators like Nxera (Singtel), Equinix, ST Telemedia, and Keppel DC REIT dominate the market. AirTrunk's SGP2 project is set to be one of the largest with over 70 MW ca

Tokyo, Japan and Cambridge, UK, 15 April 2026 – Nxera Pharma Co. Ltd (“Nxera” or the “Company”; TSE 4565) announces that, in connection with the introduction of the Employee Stock Ownership Plan for employees residing in Japan (“J-ESOP”), as announced on 19 November 2025, it has resolved to issue new shares of the Company (the "J-ESOP Share Issuance") as set out below. The J-ESOP Share Issuance is intended to secure the shares required for the operation of J-ESOP, including in connection with th

Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ® is approved through Taiwan’s Streamlined Review Designation pathway Tokyo, Japan and Cambridge, UK, 14 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical distribution and commercialization company based in Taipei, Taiw